PharmacoGenomics (PGx)
Pharmacogenomics Testing is a cutting-edge field that combines the study of genetics with the science of pharmacology. By analyzing an individual's genetic makeup, we can uncover crucial information about how their body processes and metabolizes medications. This invaluable knowledge allows healthcare professionals to make more informed decisions when prescribing drugs, reducing the risk of adverse reactions and optimizing treatment outcomes.
-
Talk to your provider about ordering PGx and how it benefits you.
-
If the test is ordered by your provider, and you do not have medical necessity but for the preventive approach it costs $300
What are the benefits of PGx Testing?
-
Eliminate the need for the “Trial and Error” method.
-
Pharmacogenetic (PGx) Testing is one of our greatest assets in preventing adverse drug reactions. These tests analyze genetic information to predict how individuals will respond to specific medications.
-
Save patients much-needed money by eliminating the co-pays of unnecessary medications.
-
Decreasing the annual number of patient hospitalizations caused by drug-gene interactions.
Pharmacogenomics is the study of how genes affect a person's response to drugs. This field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop a safe and effective therapeutic treatment that will be tailored to a person's genetic makeup.
Why Pharmacogenomics
Providers use both subjective and objective data to select and manage a patient's medication therapy. Subjective data includes the patient's personal experiences, views, or feelings. The patient's vital signs, physical exam findings, laboratory test data, and imaging results define objective data. The provider's goal is to select medications and medication doses that are effective and non-toxic for the patient.
Research has found that when providers integrate pharmacogenomics test results into a patient's medication therapy management plan, the patient may experience effective and non-toxic medication outcomes and decreased medication related costs.
References:
References: 1. Bradley P et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. Journal of Psychiatric Research. 2018. 2. Maciel A et al. Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings. Neuropsychiatr Dis Treat. 2018. 3. Winner JG et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in alyear prospective evaluation. Current Medical Research and Opinion. 2015, 4. Jablonski M et al. Economic Outcomes Following Combinatorial Pharmacogenomic Testing for Elderly Psychiatric Patients. Journal of Geriatric Psychiatry and Neurology. 2020.